Development and characterization of docetaxel-loaded nanoparticles for docetaxel-resistant castration-resistant prostate cancer

Asama Tanaudommongkon, Irin Tanaudommongkon, Priyanka Prathipati, Joey Nguyen, Xiaowei Dong

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The objective of the present study is to develop novel docetaxel nanoparticles to treat docetaxel-resistant castration-resistant prostate cancer. Oils and surfactants used to prepare docetaxel nanoparticles were selected based on the solubility test. Docetaxel nanoparticles were prepared by an emulsion method using Migloyl 812 as the oil phase and D-α-tocopheryl polyethylene glycol 1000 succinate as the surfactant phase. The nanoparticles were characterized in terms of particle size, zeta potential, polydispersity index, long-term stability, drug loading, drug entrapment efficiency, in vitro release study, differential scanning calorimetry analysis, and cytotoxicity studies in the sensitive and resistant castration-resistant prostate cancer cell lines of PC3 and DU145. All tested nanoparticles had particle size less than 120 nm with narrow size distribution. Docetaxel nanoparticles were physically stable at 4°C over six months. Drug entrapment efficiency was over 93%, with drug loading of 3.5% (drug/total excipients, w/w). The result of differential scanning calorimetry showed that docetaxel was present as amorphous in docetaxel nanoparticles. The cytotoxicity studies demonstrated that the IC50 values of docetaxel nanoparticles and free docetaxel for the sensitive cell lines were comparable. For the docetaxel-resistant cell lines, docetaxel nanoparticles significantly reduced the IC50 values when compared to those of free docetaxel. Therefore, docetaxel nanoparticles have potential to treat docetaxel-resistant castration-resistant prostate cancer.

Original languageEnglish
Pages (from-to)3920-3926
Number of pages7
JournalJournal of Nanoscience and Nanotechnology
Volume17
Issue number6
DOIs
StatePublished - 1 Jan 2017

Fingerprint

docetaxel
Castration
Nanoparticles
Prostatic Neoplasms
cancer
nanoparticles
drugs
cultured cells
entrapment
Cells
Cytotoxicity
Differential scanning calorimetry
Pharmaceutical Preparations
Surface active agents
Differential Scanning Calorimetry
heat measurement
oils
Particle size
surfactants
Particle Size

Keywords

  • Docetaxel
  • Docetaxel-resistant castration-resistant prostate cancer
  • Lipid nanoparticles

Cite this

Tanaudommongkon, Asama ; Tanaudommongkon, Irin ; Prathipati, Priyanka ; Nguyen, Joey ; Dong, Xiaowei. / Development and characterization of docetaxel-loaded nanoparticles for docetaxel-resistant castration-resistant prostate cancer. In: Journal of Nanoscience and Nanotechnology. 2017 ; Vol. 17, No. 6. pp. 3920-3926.
@article{ebc1b07a4b9e4ee9a9e67ae44549a450,
title = "Development and characterization of docetaxel-loaded nanoparticles for docetaxel-resistant castration-resistant prostate cancer",
abstract = "The objective of the present study is to develop novel docetaxel nanoparticles to treat docetaxel-resistant castration-resistant prostate cancer. Oils and surfactants used to prepare docetaxel nanoparticles were selected based on the solubility test. Docetaxel nanoparticles were prepared by an emulsion method using Migloyl 812 as the oil phase and D-α-tocopheryl polyethylene glycol 1000 succinate as the surfactant phase. The nanoparticles were characterized in terms of particle size, zeta potential, polydispersity index, long-term stability, drug loading, drug entrapment efficiency, in vitro release study, differential scanning calorimetry analysis, and cytotoxicity studies in the sensitive and resistant castration-resistant prostate cancer cell lines of PC3 and DU145. All tested nanoparticles had particle size less than 120 nm with narrow size distribution. Docetaxel nanoparticles were physically stable at 4°C over six months. Drug entrapment efficiency was over 93{\%}, with drug loading of 3.5{\%} (drug/total excipients, w/w). The result of differential scanning calorimetry showed that docetaxel was present as amorphous in docetaxel nanoparticles. The cytotoxicity studies demonstrated that the IC50 values of docetaxel nanoparticles and free docetaxel for the sensitive cell lines were comparable. For the docetaxel-resistant cell lines, docetaxel nanoparticles significantly reduced the IC50 values when compared to those of free docetaxel. Therefore, docetaxel nanoparticles have potential to treat docetaxel-resistant castration-resistant prostate cancer.",
keywords = "Docetaxel, Docetaxel-resistant castration-resistant prostate cancer, Lipid nanoparticles",
author = "Asama Tanaudommongkon and Irin Tanaudommongkon and Priyanka Prathipati and Joey Nguyen and Xiaowei Dong",
year = "2017",
month = "1",
day = "1",
doi = "10.1166/jnn.2017.13089",
language = "English",
volume = "17",
pages = "3920--3926",
journal = "Journal of Nanoscience and Nanotechnology",
issn = "1533-4880",
publisher = "American Scientific Publishers",
number = "6",

}

Development and characterization of docetaxel-loaded nanoparticles for docetaxel-resistant castration-resistant prostate cancer. / Tanaudommongkon, Asama; Tanaudommongkon, Irin; Prathipati, Priyanka; Nguyen, Joey; Dong, Xiaowei.

In: Journal of Nanoscience and Nanotechnology, Vol. 17, No. 6, 01.01.2017, p. 3920-3926.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Development and characterization of docetaxel-loaded nanoparticles for docetaxel-resistant castration-resistant prostate cancer

AU - Tanaudommongkon, Asama

AU - Tanaudommongkon, Irin

AU - Prathipati, Priyanka

AU - Nguyen, Joey

AU - Dong, Xiaowei

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The objective of the present study is to develop novel docetaxel nanoparticles to treat docetaxel-resistant castration-resistant prostate cancer. Oils and surfactants used to prepare docetaxel nanoparticles were selected based on the solubility test. Docetaxel nanoparticles were prepared by an emulsion method using Migloyl 812 as the oil phase and D-α-tocopheryl polyethylene glycol 1000 succinate as the surfactant phase. The nanoparticles were characterized in terms of particle size, zeta potential, polydispersity index, long-term stability, drug loading, drug entrapment efficiency, in vitro release study, differential scanning calorimetry analysis, and cytotoxicity studies in the sensitive and resistant castration-resistant prostate cancer cell lines of PC3 and DU145. All tested nanoparticles had particle size less than 120 nm with narrow size distribution. Docetaxel nanoparticles were physically stable at 4°C over six months. Drug entrapment efficiency was over 93%, with drug loading of 3.5% (drug/total excipients, w/w). The result of differential scanning calorimetry showed that docetaxel was present as amorphous in docetaxel nanoparticles. The cytotoxicity studies demonstrated that the IC50 values of docetaxel nanoparticles and free docetaxel for the sensitive cell lines were comparable. For the docetaxel-resistant cell lines, docetaxel nanoparticles significantly reduced the IC50 values when compared to those of free docetaxel. Therefore, docetaxel nanoparticles have potential to treat docetaxel-resistant castration-resistant prostate cancer.

AB - The objective of the present study is to develop novel docetaxel nanoparticles to treat docetaxel-resistant castration-resistant prostate cancer. Oils and surfactants used to prepare docetaxel nanoparticles were selected based on the solubility test. Docetaxel nanoparticles were prepared by an emulsion method using Migloyl 812 as the oil phase and D-α-tocopheryl polyethylene glycol 1000 succinate as the surfactant phase. The nanoparticles were characterized in terms of particle size, zeta potential, polydispersity index, long-term stability, drug loading, drug entrapment efficiency, in vitro release study, differential scanning calorimetry analysis, and cytotoxicity studies in the sensitive and resistant castration-resistant prostate cancer cell lines of PC3 and DU145. All tested nanoparticles had particle size less than 120 nm with narrow size distribution. Docetaxel nanoparticles were physically stable at 4°C over six months. Drug entrapment efficiency was over 93%, with drug loading of 3.5% (drug/total excipients, w/w). The result of differential scanning calorimetry showed that docetaxel was present as amorphous in docetaxel nanoparticles. The cytotoxicity studies demonstrated that the IC50 values of docetaxel nanoparticles and free docetaxel for the sensitive cell lines were comparable. For the docetaxel-resistant cell lines, docetaxel nanoparticles significantly reduced the IC50 values when compared to those of free docetaxel. Therefore, docetaxel nanoparticles have potential to treat docetaxel-resistant castration-resistant prostate cancer.

KW - Docetaxel

KW - Docetaxel-resistant castration-resistant prostate cancer

KW - Lipid nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85016451507&partnerID=8YFLogxK

U2 - 10.1166/jnn.2017.13089

DO - 10.1166/jnn.2017.13089

M3 - Article

VL - 17

SP - 3920

EP - 3926

JO - Journal of Nanoscience and Nanotechnology

JF - Journal of Nanoscience and Nanotechnology

SN - 1533-4880

IS - 6

ER -